References
- ZebaryAOmholtKVassilakiIKIT, NRAS, BRAF, and PTEN mutations in a sample of Swedish patients with acral lentiginous melanomaJ Dermatol Sci201372328428923993026
- Van RaamsdonkCDGriewankKGCrosbyMBMutations in GNA11 in uveal melanomaN Engl J Med2010363232191219921083380
- BishopDTDemenaisFGoldsteinAMGeographical variation in the penetrance of CDKN2A mutations for melanomaJ Natl Cancer Inst2002941289490312072543
- MiddletonMRGrobJJAaronsonNRandomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaJ Clin Oncol200018115816610623706
- KiebertGMJonasDLMiddletonMRHealth-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazineCancer Invest200321682182914735685
- LuoCShenJResearch progress in advanced melanomaCancer Lett201739712012628385603
- UgurelSRapplGTilgenWReinholdUIncreased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survivalJ Clin Oncol200119257758311208853
- CuiCMaoLChiZA phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanomaMol Ther20132171456146323670576
- Piperno-NeumannSDialloAEtienne-GrimaldiMCPhase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanomaOncologist201621328128226911405
- KottschadeLASumanVJPerezDGA randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775Cancer2013119358659222915053
- von MoosRSeifertBSimcockMFirst-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)Ann Oncol201223253153621527587
- TianSQuanHXieCYN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro, and in vivoCancer Sci201110271374138021443688
- MiYJLiangYJHuangHBApatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transportersCancer Res201070207981799120876799
- LiGSatyamoorthyKHerlynMN-cadherin-mediated intercellular interactions promote survival and migration of melanoma cellsCancer Res20016193819382511325858
- SmalleyKSSondakVKWeberJSc-KIT signaling as the driving oncogenic event in sub-groups of melanomasHistol Histopathol200924564365019283671
- GuoJSiLKongYPhase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplificationJ Clin Oncol201129212904290921690468
- JiGHongLYangPSuccessful treatment of angiosarcoma of the scalp with apatinib: a case reportOnco Targets Ther201694989499227563253
- DongMBiJLiuXWangBWangJSignificant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: a case reportMedicine20169531e436827495042